Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
“Since joining the company earlier this year, Bren has made significant contributions preparing our manufacturing facility in Redwood City to commence operations, and I believe he is the ideal candidate to serve as the company’s Chief Operating Officer going forward,” stated Michael Rowe, Chief Executive Officer of Eyenovia.
- “Since joining the company earlier this year, Bren has made significant contributions preparing our manufacturing facility in Redwood City to commence operations, and I believe he is the ideal candidate to serve as the company’s Chief Operating Officer going forward,” stated Michael Rowe, Chief Executive Officer of Eyenovia.
- Eyenovia also announced today that independent director Julia Haller, MD is stepping down from the company’s Board of Directors.
- Developed as a micro-formulation for use without anesthetic, Eyenovia believes Mydcombi will help improve the efficacy, tolerability, and efficiency of pharmacologic mydriasis.
- Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics.